Stoke Therapeutics (STOK) Preferred Shares (2018)
Stoke Therapeutics' quarterly Preferred Shares came in at $130.3 million in Q4 2018.
Stoke Therapeutics has reported Preferred Shares for 1 years, with the latest figure at $130.3 million in Q4 2018.
- For the quarter ending Q4 2018, Preferred Shares changed N/A year-over-year to $130.3 million; the trailing twelve-month figure through Dec 2018 stood at $130.3 million (changed N/A YoY), and the FY2018 full-year result was $130.3 million, changed N/A from the prior year.
- Preferred Shares for Q4 2018 stood at $130.3 million.
- The five-year high for Preferred Shares was $130.3 million in Q4 2018, with the low at $130.3 million in Q4 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 130.35 Mn |